Voyager Therapeutics, Inc. (VYGR)

Market Cap	230.52M
Revenue (ttm)	163.78M
Net Income (ttm)	25.88M
Shares Out	54.63M
EPS (ttm)	0.47
PE Ratio	9.05
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	260,687
Open	4.290
Previous Close	4.260
Day's Range	4.205 - 4.354
52-Week Range	4.000 - 10.660
Beta	0.91
Analysts	Strong Buy
Price Target	15.53 (+268.01%)
Earnings Date	Mar 3, 2025

About VYGR

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therap...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 162
• Stock Exchange: NASDAQ
• Ticker Symbol: VYGR
• Website: https://www.voyagertherapeutics.com

Analyst Forecast

According to 9 analysts, the average rating for VYGR stock is "Strong Buy." The 12-month stock price forecast is $15.53, which is an increase of 268.01% from the latest price.

Price Target

$15.53

(268.01% upside)

Analyst Consensus: Strong Buy